Log in

Relevant bibliographies by topics / Chronic obstructive pulmonary disease complicated pulmonary arterial hypertension / Journal articles

To see the other types of publications on this topic, follow the link: Chronic obstructive pulmonary disease complicated pulmonary arterial hypertension.

Journal articles on the topic 'Chronic obstructive pulmonary disease complicated pulmonary arterial hypertension'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chronic obstructive pulmonary disease complicated pulmonary arterial hypertension.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Меньшикова, Ираида, Iraida Men'shikova, Юлия Квасникова, et al. "CARDIORENAL INTERRELATIONSHIPS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE." Bulletin physiology and pathology of respiration 1, no. 68 (2018): 29–33. http://dx.doi.org/10.12737/article_5b1894ebea7e63.33544844.

Full text

Abstract:

The aim is to study the interrelationships between the state of pulmonary, intracardiac hemodynamics and renal blood flow in patients with chronic obstructive pulmonary disease (COPD) complicated with the chronic cor pulmonale (CCP). 75 patients with COPD complicated with compensated CCP who had the study of pulmonary, intracardiac and renal hemodynamics with the method of ultrasound duplex scanning were examined. The patients were divided into 2 groups: the 1st group included 45 patients with COPD with pulmonary hypertension (PH) without clinical signs of right ventricle insufficiency; the 2n

APA, Harvard, Vancouver, ISO, and other styles

2

Valentini, Adele, Paola Franchi, Giuseppe Cicchetti, et al. "Pulmonary Hypertension in Chronic Lung Diseases: What Role Do Radiologists Play?" Diagnostics 13, no. 9 (2023): 1607. http://dx.doi.org/10.3390/diagnostics13091607.

Full text

Abstract:

Pulmonary hypertension (PH) is a pathophysiological disorder, defined by a mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest, as assessed by right heart catheterization (RHC). PH is not a specific disease, as it may be observed in multiple clinical conditions and may complicate a variety of thoracic diseases. Conditions associated with the risk of developing PH are categorized into five different groups, according to similar clinical presentations, pathological findings, hemodynamic characteristics, and treatment strategy. Most chronic lung diseases that may be complicated by PH bel

APA, Harvard, Vancouver, ISO, and other styles

3

Alyavi, A. L., Dilorom Alimovna Rakhimova, and Z. T. Sabirzhanova. "THE STATE OF ENDOTHELIUM-DEPENDENT VASOREGULATION IN THE DYNAMICS OF THE EFFECT OF A NON-DRUG THERAPY COMPLEX IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION." Russian Journal of Physiotherapy, Balneology and Rehabilitation 16, no. 6 (2017): 315–19. http://dx.doi.org/10.18821/1681-3456-2017-16-5-315-319.

Full text

Abstract:

After complex treatment with the use of ozonotherapy and bischofite electrophoresis on the background of standard therapy, the parameters of diastolic function of the right ventricle, mean pulmonary arterial pressure, the level of stable metabolites of nitric oxide, endothelium-dependent vasoregulation and psychoemotional status in patients with chronic obstructive pulmonary disease complicated by the development of chronic pulmonary heart were improved against standard therapy.

APA, Harvard, Vancouver, ISO, and other styles

4

Guo, Feng-Xia, Xiao-Chuan Zhu, Xin Hu, and De-Jie Chu. "The treatment of acute exacerbation of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension." Asian Journal of Surgery 45, no. 1 (2022): 590–91. http://dx.doi.org/10.1016/j.asjsur.2021.10.045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Li, V. V., V. S. Zadionchenko, T. V. Adasheva, S. V. Pavlov, and N. B. Shakhrai. "Chronic obstructive pulmonary disease and arterial hypertension: methaphysics and dialectic." CardioSomatics 4, no. 1 (2013): 5–10. http://dx.doi.org/10.26442/cs44977.

Full text

Abstract:

The paper provides a review of prevalence and outcomes of cardiovascular comorbidities in patients with chronic obstructive pulmonary disease (COPD). From a clinical and patient-centered perspective, a COPD phenotype should be able to classify patients into distinct subgroups that provide prognostic information and allow to better determine appropriate therapy that alters clinically meaningful outcomes. It is hypothesized that both COPD and artherial hypertension (AH) have common pathway linking these comorbidities and explaining why they significantly complicate the management and influence t

APA, Harvard, Vancouver, ISO, and other styles

6

Amer, Eman A., Taimor M. Abdullah, Mohamed S. Hantera, and Basem I. Elshafey. "Six minutes-walk test in chronic obstructive pulmonary disease patients complicated by pulmonary hypertension diagnosed by echocardiography." Tanta Medical Journal 53, no. 1 (2025): 103–8. https://doi.org/10.4103/tmj.tmj_16_24.

Full text

Abstract:

Background Chronic obstructive pulmonary disease (COPD) is heterogenous lung condition characterized by chronic respiratory symptoms. Aim To assess 6 minutes-walk-test in COPD patients who develop secondary pulmonary hypertension (PH) diagnosed by echocardiography. Patients and methods This comparative interventional study included 30 individuals categorized into three equal groups: group I: healthy persons (mean age 38.90±4.53), group II: COPD patients (mean age 46.40±4.65) and group III: COPD patients complicated with secondary PH (mean age 58.00±4.37). Results There was significant positive

APA, Harvard, Vancouver, ISO, and other styles

7

Ali, Qaisar, Akhtar Ali khan, Muhammad Zeeshan, Hafiz Muhammad Mudasir, Farid Ullah, and Farhan Shahzad. "FREQUENCY OF PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE PRESENTING AT TERTIARY CARE HOSPITAL." Insights-Journal of Health and Rehabilitation 3, no. 2 (Health & Rehab) (2025): 334–40. https://doi.org/10.71000/b5ky7h76.

Full text

Abstract:

Background: Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder frequently complicated by pulmonary hypertension (PH), a condition associated with increased morbidity and mortality. PH in COPD results from chronic hypoxia and vascular remodeling, potentially leading to right heart failure. The prevalence of PH varies widely among COPD patients, influenced by disease severity, diagnostic methods, and regional factors. Identifying the burden of PH in COPD is essential for timely intervention and improved clinical outcomes. Objective: To assess the frequency of pulm

APA, Harvard, Vancouver, ISO, and other styles

8

Gonzales, Janae, and Dustin R. Fraidenburg. "Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease." Pharmaceuticals 16, no. 3 (2023): 418. http://dx.doi.org/10.3390/ph16030418.

Full text

Abstract:

Pulmonary hypertension (PH) frequently complicates chronic lung disease and is associated with high morbidity and poor outcomes. Individuals with interstitial lung disease and chronic obstructive pulmonary disease develop PH due to structural changes associated with the destruction of lung parenchyma and vasculature with concurrent vasoconstriction and pulmonary vascular remodeling similar to what is observed in idiopathic pulmonary arterial hypertension (PAH). Treatment for PH due to chronic lung disease is largely supportive and therapies specific to PAH have had minimal success in this popu

APA, Harvard, Vancouver, ISO, and other styles

9

Ghigna, Maria Rosa, Wolter J. Mooi, and Katrien Grünberg. "Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia." European Respiratory Review 26, no. 144 (2017): 170003. http://dx.doi.org/10.1183/16000617.0003-2017.

Full text

Abstract:

Pulmonary hypertension (PH) with complicating chronic lung diseases and/or hypoxia falls into group 3 of the updated classification of PH. Patients with chronic obstructive lung disease (COPD), diffuse lung disease (such as idiopathic pulmonary fibrosis (IPF)) and with sleep disordered breathing are particularly exposed to the risk of developing PH. Although PH in such a context is usually mild, a minority of patients exhibit severe haemodynamic impairment, defined by a mean pulmonary arterial pressure (mPAP) of ≥35 mmHg or mPAP values ranging between 25 mmHg and 35 mmHg with a low cardiac ind

APA, Harvard, Vancouver, ISO, and other styles

10

Ostrovskyy, M. M., I. H. Kupnovytska, L. A. Dron, et al. "Features of the Influence of Chronic Obstructive Pulmonary Disease on the Structural and Functional Parameters of the Heart and Vessels: Possibilities for Correction." Tuberculosis, Lung Diseases, HIV Infection, no. 3 (September 20, 2023): 11–19. http://dx.doi.org/10.30978/tb-2023-3-11.

Full text

Abstract:

The presence of concomitant cardiac pathology exacerbates the course of chronic obstructive pulmonary disease (COPD) and worsens the prognosis for both conditions. Objective — to improving the efficiency of diagnostics and treatment in patients with arterial hypertension and COPD, adding L-arginine to the complex therapy. Materials and methods. A clinical examination was performed on a total of 140 patients, consisting of 82 individuals with arterial hypertension complicated by chronic obstructive pulmonary disease (COPD), and 58 patients with isolated hypertension. Each group was further subd

APA, Harvard, Vancouver, ISO, and other styles

11

Mohamed Saeed, Dr Murwan. "Prevalence and Presentation of Pulmonary Hypertension Among COPD Patients in Port Sudan Teaching Hospital." International Journal of Advanced Multidisciplinary Research and Studies 5, no. 4 (2025): 294–97. https://doi.org/10.62225/2583049x.2025.5.4.4580.

Full text

Abstract:

Background: Pulmonary hypertension is a critical medical problem that result in significant morbidity and mortality and it defined as mean pulmonary arterial pressure (mPAP >20 mmHg) at rest. Pulmonary hypertension classified into 5 groups these are: Pulmonary arterial hypertension, Pulmonary hypertension due to left heart disease, Pulmonary hypertension due to lung disease, Chronic thromboembolic pulmonary hypertension and Pulmonary hypertension with unclear or multifactorial causes. COPD is define as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, co

APA, Harvard, Vancouver, ISO, and other styles

12

Ye, Haifeng. "Risk factors and establishment of a nomogram model for pulmonary arterial hypertension complicated by acute exacerbation of chronic obstructive pulmonary disease." American Journal of Translational Research 17, no. 5 (2025): 3917–27. https://doi.org/10.62347/xmte6690.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Մինասյան Ա.Մ., Խաչատրյան Թ.Ա., Մելքոնյան Է.Գ., Մելոյան Ս.Վ. та Տավարացյան Ա.Ռ. "ԹՈՔԱՅԻՆ ԶԱՐԿԵՐԱԿԱՅԻՆ ՀԻՊԵՐՏԵՆԶԻԱ". MEDICINE, SCIENCE AND EDUCATION, № 36 (листопад 2023): 16–22. http://dx.doi.org/10.56936/18291775-2023.36-16.

Full text

Abstract:

Pulmonary hypertension (PH) is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive rise in the pulmonary vascular load, leading to hypertrophy and remodeling of the right ventricle. PH hemodynamically defined hemodynamically by a mean pulmonary arterial pressure of higher than 20 mm Hg at rest, as measured by right heart catheterization. The several forms of PH are categorized into five clinical groups, based on the 2018 meeting of the World Symposium on PH with the clinical characteristics and hemodynamic profile of each group. PH complicates chronic l

APA, Harvard, Vancouver, ISO, and other styles

14

Zuo, Huanhuan, Xiaochen Xie, Jiahuan Peng, Lixin Wang, and Rong Zhu. "Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease." Analytical Cellular Pathology 2019 (October 14, 2019): 1–9. http://dx.doi.org/10.1155/2019/5189165.

Full text

Abstract:

Recently, there has been an increasing interest in the potential clinical use of several inflammatory indexes, namely, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic-immune-inflammation index (SII). This study aimed at assessing whether these markers could be early indicators of pulmonary hypertension (PH) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). A total of 185 patients were enrolled in our retrospective study from January 2017 to January 2019. Receiver operating characteristic curve (ROC) and area under the

APA, Harvard, Vancouver, ISO, and other styles

15

Shogenova, Ludmila V. "Efficacy and safety of combined therapy with thermal heliox and nitric oxide during noninvasive ventilation in patients with acute chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary hypertension." Consilium Medicum 27, no. 3 (2025): 159–64. https://doi.org/10.26442/20751753.2025.3.203177.

Full text

Abstract:

Aim. To study the efficacy and safety of combination therapy of thermal heliox (t-He/O2) and nitric oxide (NO) in patients with acute chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary arterial hypertension (PAH) [group III PAH according to the classification of the World Health Organization]. Materials and methods. The study included 180 patients (GOLD C/D) divided into four groups: Group 1 (t-He/O₂ + non-invasive ventilation – NIV), Group 2 (NO + NIV), Group 3 (t-He/O₂ + NO + NIV), and Group 4 (control, receiving NIV alone)

APA, Harvard, Vancouver, ISO, and other styles

16

LeMaster, William, Dale Jun, Sharon De Cruz, Michelle Zeidler, and Rajan Saggar. "824 Case Series on the Use of Volume Assured Pressure Support in Patients with Chronic Pulmonary Disease and Progressive Hypercapnia." Sleep 44, Supplement_2 (2021): A321—A322. http://dx.doi.org/10.1093/sleep/zsab072.821.

Full text

Abstract:

Abstract Introduction Chronic hypercapnia results from destruction of lung parenchyma which occurs in chronic lung diseases including interstitial lung disease (ILD), bronchiectasis, and chronic lung transplant rejection. Many patients with these diseases will experience progressive respiratory failure eventually requiring consideration of transplantation or re-transplantation. Due to physiologic changes in sleep including reduction in tidal volume, worsening air tapping, and REM atonia, hypoventilation can be exacerbated during the sleeping hours. We present four patients who were prescribed

APA, Harvard, Vancouver, ISO, and other styles

17

Halushko, O. A., O. A. Loskutov, M. A. Trishchynska, I. A. Kuchynska, and M. V. Boliuk. "Main causes of complicated COVID-19 in patients with diabetes mellitus." EMERGENCY MEDICINE 17, no. 4 (2021): 23–31. http://dx.doi.org/10.22141/2224-0586.17.4.2021.237723.

Full text

Abstract:

Background. Since December 2019, the new coronavirus disease 2019 (COVID-19) has been marching confidently and aggressively across the planet. On March 11, 2020, the World Health Organization has declared COVID-19 a pandemic. Among the risk factors for the development and severe course of COVID-19, there are old age, arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease, cardiovascular and cerebrovascular diseases. However, recently, based on the epidemiological data obtained, diabetes mellitus is no longer considered a risk factor for infection with SARS-CoV-2, but t

APA, Harvard, Vancouver, ISO, and other styles

18

Shogenova, Ludmila V. "Efficiency and safety of the integrated use of medical gases thermal heliox, nitric oxide and molecular hydrogen in patients with exacerbation of chronic obstructive pulmonary disease complicated by hypoxemic, hypercapnic respiratory failure and secondary pulmonary arterial hypertension in the post-COVID period." Terapevticheskii arkhiv 97, no. 3 (2025): 242–49. https://doi.org/10.26442/00403660.2025.03.203131.

Full text

Abstract:

Aim. To study the efficacy and safety of the combined use of thermal heliox (t-He/O2), nitric oxide (NO) and molecular hydrogen (H2) in patients with exacerbation of chronic obstructive pulmonary disease (COPD) complicated by hypoxemic, hypercapnic respiratory failure (RF) and secondary pulmonary arterial hypertension (PAH) in the post-COVID period. Materials and methods. The randomized, comparative, controlled, parallel study included patients (n=100, 52 men and 48 women) with exacerbation of COPD levels of evidence C and D (GOLD 2021–2023) with hypoxemic, hypercapnic respiratory failure and

APA, Harvard, Vancouver, ISO, and other styles

19

Rasputina, Lesya, and Daria Didenko. "PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PATIENTS WITH CORONARY HEART DISEASE AND ARTERIAL HYPERTENSION." EUREKA: Health Sciences 2 (March 31, 2017): 38–45. http://dx.doi.org/10.21303/2504-5679.2017.00320.

Full text

Abstract:

The prevalence of chronic obstructive pulmonary disease among patients with cardio-vascular diseases is higher than in general population. At the same time the one of problems of internal medicine is a timely diagnostics of chronic obstructive pulmonary disease. The aim of the work was the study of prevalence of chronic obstructive pulmonary disease among patients with cardio-vascular diseases, especially arterial hypertension and coronary heart disease. Materials and methods. The retrospective analysis of statistical cards of patients, who were on stationary treatment at therapeutic departmen

APA, Harvard, Vancouver, ISO, and other styles

20

Bagisheva, Natalia V., Anna V. Mordyk, Dmitry I. Trukhan, et al. "Correction of therapy of concerned cardiovascular disease and chronic obstructive pulmonary disease in a patient with pulmonary tuberculo." Clinical review for general practice 2, no. 10 (2021): 6–9. http://dx.doi.org/10.47407/kr2021.2.10.00111.

Full text

Abstract:

Chronic obstructive pulmonary disease and cardiovascular diseases (arterial hypertension, coronary heart disease, chronic heart failure) are among the comorbid conditions that mutually aggravate each other. The addition of tuberculosis in this category of patients requires additional efforts from the doctor to improve treatment outcomes. A clinical example of correction of therapy for arterial hypertension and chronic obstructive pulmonary disease in a patient with pulmonary tuberculosis is presented.

APA, Harvard, Vancouver, ISO, and other styles

21

Akramova, E. G. "Ultrasonic indicators of the heart and carotid arteries in arterial hypertension development in patients with chronic obstructive pulmonary disease." Kazan medical journal 97, no. 4 (2016): 496–501. http://dx.doi.org/10.17750/kmj2015-496.

Full text

Abstract:

Aim. To specify the sequence of changes in the functional parameters of arterial hypertension in patients with chronic obstructive pulmonary disease and asthma according to the results of echocardiography, carotid arteries duplex scan and ambulatory blood pressure monitoring.Methods. Ambulatory blood pressure monitoring, tissue Doppler echocardiography and carotid artery duplex scan were performed in 160 patients with chronic obstructive pulmonary disease, arterial hypertension, asthma, and 33 apparently healthy volunteers of both sexes aged 39-70 years.Results. In patients with chronic obstru

APA, Harvard, Vancouver, ISO, and other styles

22

Padyganova, A. V. "Phenotype of chronic obstructive pulmonary disease at women with arterial hypertension: features of the functional condition of kidneys." CardioSomatics 6, no. 2 (2015): 40–46. http://dx.doi.org/10.26442/cs45147.

Full text

Abstract:

The prevalence of concomitant cardiovascular and pulmonary diseases is high. In this article features of a current of an arterial hypertension with chronic obstructive pulmonary disease taking into account a gender factor are surveyed. Results of own analysis of these case histories of patients with chronic obstructive pulmonary disease and the arterial hypertension (n=133), the level which has taped reliable rising of a cholesterin at patients at association of pathology of respiratory system and circulation organs are presented. Also in article the questions concerning features of a function

APA, Harvard, Vancouver, ISO, and other styles

23

Gajnitdinova, V. V., A. B. Bakirov, E. Kh Akhmetzyanova, N. F. Berdikaeva, and V. B. Zakirova. "Arterial stiffness of peripheral vasculature in patients with chronic obstructive pulmonary disease and its association with arterial hypertension." Kazan medical journal 94, no. 6 (2013): 808–12. http://dx.doi.org/10.17816/kmj1795.

Full text

Abstract:

Aim. To study the structural and functional state of vascular wall, arterial stiffness of large peripheral arteries (common carotid arteries, renal arteries) in patients with severe chronic obstructive pulmonary disease and its association with arterial hypertension. Methods. The study included 67 patients of working age, mainly males, having chronic obstructive pulmonary disease. Among them, 52 patients had severe chronic obstructive pulmonary disease (defined by GOLD III, 2011), 15 had concomitant arterial hypertension of I and II stage. Structural and functional status of common carotid art

APA, Harvard, Vancouver, ISO, and other styles

24

Karyana, Levina. "Pharmaceutical Therapies for Chronic Obstructive Pulmonary Disease Complicated by Pulmonary Hypertension." Science Insights 41, no. 3 (2022): 639–44. http://dx.doi.org/10.15354/si.22.re078.

Full text

Abstract:

As a chronic lung condition, chronic obstructive pulmonary disease (COPD) is well-known. As our understanding of COPD’s consequences has grown, pulmonary hypertension (PH) has drawn a growing amount of attention. Patients’ quality of life is significantly impacted by the higher mortality and poor prognosis of COPD patients with PH, and there are still no effective medications available to treat the condition. The development of medication therapy for COPD complicated by PH was examined in order to fully comprehend the state of the disease’s treatment at the moment. The findings suggest that fo

APA, Harvard, Vancouver, ISO, and other styles

25

Bagisheva, N. V., A. V. Mordyk, I. A. Viktorova, and D. I. Trukhan. "Cardiovascular pathology in patients with newly diagnosed tuberculosis and chronic obstructive pulmonary disease." Meditsinskiy sovet = Medical Council, no. 14 (October 18, 2021): 142–48. http://dx.doi.org/10.21518/2079-701x-2021-14-142-148.

Full text

Abstract:

Introduction. Chronic obstructive pulmonary disease and cardiovascular diseases (arterial hypertension, ischemic heart disease, chronic heart failure) are among the comorbid conditions that mutually aggravate each other. The addition of tuberculosis in this category of patients requires additional efforts from the doctor to improve treatment outcomes.Purpose. Тo assess the prevalence of chronic obstructive pulmonary disease, arterial hypertension, coronary heart disease and chronic heart failure in patients with newly diagnosed tuberculosis hospitalized in an anti-tuberculosis hospital.Materia

APA, Harvard, Vancouver, ISO, and other styles

26

Akramova, E. G. "The features of time characteristics of heart rate variability in chronic obstructive pulmonary disease." Kazan medical journal 93, no. 2 (2012): 172–77. http://dx.doi.org/10.17816/kmj2281.

Full text

Abstract:

Aim. To study the features of time characteristics of heart rate variability during isolated chronic obstructive pulmonary disease, as well as in association with arterial hypertension and ischemic heart disease. Methods. The characteristics of heart rate variability using Holter electrocardiography monitoring, echocardiography and duplex scanning of carotid arteries were studied. The results of investigations of 298 individuals of both sexes aged 37-78 years were included into the analysis, including 79 patients with chronic obstructive pulmonary disease who were divided into three groups. Th

APA, Harvard, Vancouver, ISO, and other styles

27

I. M., Fushtey, Podsevahina S. L., Tkachenko O. V., Palamarchuk A. I., and Cabanna E. S. "THE QUALITY LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMBINED WITH ARTERIAL HYPERTENSION." Modern medical technologies 43, no. 4 (2019): 4–9. http://dx.doi.org/10.34287/mmt.4(43).2019.1.

Full text

Abstract:

Abstract Purpose of the study. Was to investigate life quality in patients with comorbidly pathology of chronic obstructive pulmonary disease in combination with arterial hypertension. Materials and methods. 77 subjects with a diagnosis of chronic obstructive pulmonary disease stage I–III (according to the GOLD criteria) in combination with arterial hypertension I–III stage. The comparison groups included 30 patients with essential hypertension and 45 patients with chronic obstructive pulmonary disease. All groups were completely comparable by the length and disease severity. All patients unde

APA, Harvard, Vancouver, ISO, and other styles

28

Kakar, Iftikhar Ali, Abdul Baqi, Nasir Azim, Hafsa Rafiq, Iqra Lodhi, and Khalid Shahab. "Pulmonary Arterial Hypertension in COPD and its Correlation with Disease Severity." Pakistan Journal of Medical and Health Sciences 16, no. 12 (2022): 391–93. http://dx.doi.org/10.53350/pjmhs20221612391.

Full text

Abstract:

Background: Pulmonary arterial hypertension is a condition that develops in advanced stages of chronic obstructive pulmonary disease. The development of pulmonary arterial hypertension indicate poor prognosis. Objective: To assess the arterial hypertension in COPD and its correlation with disease severity Methodology: This descriptive study was carried out at the Pulmonology department, Fatima Jinnah Institute of Chest Diseases and Sheikh Khalifa Bin Zayyed Al Nahyan Medical Complex Quetta from December 2021 to May 2022. The severity of COPD was measured by FEV1 (spirometry). All the data was

APA, Harvard, Vancouver, ISO, and other styles

29

Dielievska, V. Yu, and I. P. Dunaeva. "AUTOIMMUNE MECHANISMS OF CHRONIC HEART FAILURE PROGRESSION IN ARTERIAL HYPERTENSION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CONCOMITANT TYPE 2 DIABETES MELLITU." Problems of Endocrine Pathology 55, no. 1 (2016): 23–28. http://dx.doi.org/10.21856/j-pep.2016.1.03.

Full text

Abstract:

We examined whether autoantibodies against type IV collagen are associated with heart failure progression in arterial hypertension combined with chronic obstructive pulmonary disease with and without type 2 diabetes mellitus. Both patients with chronic heart failure in essential hypertension and chronic obstructive pulmonary disease and patients with concomitant type 2 diabetes mellitus showed higher levels of plasma type IV collagen autoantibodies in comparison to healthy controls. Type IV collagen antibodies correlated with dilation of the left ventricle and reduction of its contractility. E

APA, Harvard, Vancouver, ISO, and other styles

30

Marushchak, Mariya, Khrystyna Maksiv, Inna Krynytska, Olha Dutchak, and Nina Behosh. "The Severity of Oxidative Stress in Comorbid Chronic Obstructive Pulmonary Disease (COPD) and Hypertension: Does it Depend On ACE and AGT Gene Polymorphisms?" Journal of Medicine and Life 12, no. 4 (2019): 426–34. http://dx.doi.org/10.25122/jml-2019-0108.

Full text

Abstract:

There is an increasing number of studies suggesting the role of genetic factors in the development and progression of chronic obstructive pulmonary disease and hypertension. Therefore, our study aimed to establish the role of ACE and AGT gene polymorphisms in the mechanisms behind the development of oxidative stress in patients with concomitant chronic obstructive pulmonary disease and hypertension. The study group consisted of 96 patients: Group 1 (individuals with a chronic obstructive pulmonary disease), Group 2 (individuals with arterial hypertension), Group 3 (individuals with a chronic o

APA, Harvard, Vancouver, ISO, and other styles

31

Spiropoulos, K., N. Charokopos, T. Petsas, et al. "Non-Invasive Estimation of Pulmonary Arterial Hypertension in Chronic Obstructive Pulmonary Disease." Lung 177, no. 2 (1999): 65–75. http://dx.doi.org/10.1007/pl00007631.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tsangaris, Iraklis, Georgios Tsaknis, Anastasia Anthi, and Stylianos E. Orfanos. "Pulmonary Hypertension in Parenchymal Lung Disease." Pulmonary Medicine 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/684781.

Full text

Abstract:

Idiopathic pulmonary arterial hypertension (IPAH) has been extensively investigated, although it represents a less common form of the pulmonary hypertension (PH) family, as shown by international registries. Interestingly, in types of PH that are encountered in parenchymal lung diseases such as interstitial lung diseases (ILDs), chronic obstructive pulmonary disease (COPD), and many other diffuse parenchymal lung diseases, some of which are very common, the available data is limited. In this paper, we try to browse in the latest available data regarding the occurrence, pathogenesis, and treatm

APA, Harvard, Vancouver, ISO, and other styles

33

Wright, Joanne L., Manuel Cosio, and Andrew Churg. "Animal models of chronic obstructive pulmonary disease." American Journal of Physiology-Lung Cellular and Molecular Physiology 295, no. 1 (2008): L1—L15. http://dx.doi.org/10.1152/ajplung.90200.2008.

Full text

Abstract:

The mechanisms involved in the genesis of chronic obstructive pulmonary disease (COPD) are poorly defined. This area is complicated and difficult to model because COPD consists of four separate anatomic lesions (emphysema, small airway remodeling, pulmonary hypertension, and chronic bronchitis) and a functional lesion, acute exacerbation; moreover, the disease in humans develops over decades. This review discusses the various animal models that have been used to attempt to recreate human COPD and the advantages and disadvantages of each. None of the models reproduces the exact changes seen in

APA, Harvard, Vancouver, ISO, and other styles

34

PALII, Ina, Iulia RODOMAN, Daniela PALEGA, Lucia PIRTU, and Svetlana SCIUCA. "Pulmonary Hypertension in Children - New Insights of Diagnosis and Management." Romanian Journal of Cardiology 31, no. 4 (2021): 893–96. http://dx.doi.org/10.47803/rjc.2020.31.4.893.

Full text

Abstract:

Pulmonary hypertension (PH) is a pathophysiological condition that includes multiple clinical situations and can complicate most cardiovascular and respiratory diseases1. Step by step diagnosis and reviewing contemporary treatment approaches would signifi cantly impact the prognosis of pediatric patients with PH. Management of children with PH requires a multidisciplinary team with experience. PH is frequently associated with cardiac and pulmonary diseases with chronic hypoxia, obstructive respiratory disorders, chest malformations, pneumonia, acute respiratory distress, and can also develop d

APA, Harvard, Vancouver, ISO, and other styles

35

NUGRAHA, IDA BAGUS ADITYA, and IDA AYU PUTU PADMI DEVIANI. "MANAGEMENT OF PULMONAL HYPERTENSION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE." Jurnal Kedokteran Raflesia 9, no. 1 (2023): 36–47. http://dx.doi.org/10.33369/juke.v9i1.28838.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) is an obstructive pulmonary disease due to inflammatory processes of the respiratory tract and lung parenchyma. In some cases of COPD, changes in the pulmonary vessels are found which are not uncommon, causing impaired gas exchange and causing pulmonary hypertension which is associated with increased morbidity and mortality. Pulmonary hypertension is an increase in the mean pulmonary artery pressure (Pulmonary Arterial Pressure) greater than or equal to 25 mmHg at rest as assessed by a right heart catheterization procedure. Pulmonary hypertension (H

APA, Harvard, Vancouver, ISO, and other styles

36

Shtepa, O. "CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ARTERIAL HYPERTENSION: THE COMORBIDITY POTENTIATING EFFECT ON THE INCREASE IN SURFACTANT PROTEIN D LEVELS AND THE SEVERITY OF SYSTEMIC INFLAMMATION." Sciences of Europe, no. 143 (June 26, 2024): 60–64. https://doi.org/10.5281/zenodo.12540817.

Full text

Abstract:

The main objective of the study was to investigate the effect of concomitant arterial hypertension on the severity of local respiratory system damage and systemic inflammation in patients with chronic obstructive pulmonary disease. The study was aimed at evaluating the performance and diagnostic significance of surfactant protein D and C-reactive protein as a marker of lung tissue damage and the severity of local inflammation. The study included 78 patients divided into two groups. The first group included 33 patients with infectious exacerbation of chronic obstructive pulmonary disease. The s

APA, Harvard, Vancouver, ISO, and other styles

37

Zadionchenko, V. S., T. V. Adasheva, I. V. Fedorova, S. V. Pavlov, V. V. Li, and O. I. Nesterenko. "Arterial hypertension and chronic obstructive pulmonary disease: pathogenetic parallels and clinicofunctional features." CardioSomatics 1, no. 1 (2010): 31–37. http://dx.doi.org/10.26442/cs44959.

Full text

Abstract:

The great prevalence of comorbidities, such as arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD), generates a need to study the impact of COPD on the pathogenesis, course, and clinical picture of associated cardiovascular diseases. The paper analyzes the data available in the literature on the pathogenesis and course of arterial hypertension in patients with COPD. The paper also gives the authors’ data on the clinicofunctional and pathophysiological features of AH in patients with COPD. The findings suggest that the study group has clinical vascular and organ dysfunct

APA, Harvard, Vancouver, ISO, and other styles

38

Palazzini, Massimiliano, Alessandra Manes, Enrico Gotti, Fabio Dardi, Andrea Rinaldi, and Nazzareno Galiè. "Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights." Journal of Scleroderma and Related Disorders 3, no. 1 (2018): 39–42. http://dx.doi.org/10.1177/2397198317751864.

Full text

Abstract:

Pulmonary arterial hypertension is a chronic and progressive disease characterized by elevated pulmonary artery pressure and pulmonary vascular resistance leading to heart failure and premature death. Pulmonary arterial hypertension is characterized by proliferative and obstructive lesions in the distal pulmonary arteries and some descriptions include also thrombotic lesions. Despite this, in an era when multiple effective pulmonary arterial hypertension therapies are available, the role of anticoagulation in the treatment of pulmonary arterial hypertension remains uncertain. In particular, an

APA, Harvard, Vancouver, ISO, and other styles

39

Lang, Irene. "Chronic thromboembolic pulmonary hypertension: a distinct disease entity." European Respiratory Review 24, no. 136 (2015): 246–52. http://dx.doi.org/10.1183/16000617.00001115.

Full text

Abstract:

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension (PH). One disease hypothesis is that CTEPH results from the non-resolution of venous thromboembolism. CTEPH is characterised by the presence of obstructive fibrotic thromboembolic material in the major pulmonary vessels, with concomitant microvascular arteriopathy, resulting in progressive PH. The clinical presentation of CTEPH is similar to pulmonary arterial hypertension with nonspecific symptoms, but it is distinguished from pulmonary arterial hypertension by the presence of mismatched segm

APA, Harvard, Vancouver, ISO, and other styles

40

Andersen, Kasper Hasseriis, Claus Bøgelund Andersen, Finn Gustafsson, and Jørn Carlsen. "Pulmonary venous remodeling in COPD-pulmonary hypertension and idiopathic pulmonary arterial hypertension." Pulmonary Circulation 7, no. 2 (2017): 514–21. http://dx.doi.org/10.1177/2045893217709762.

Full text

Abstract:

Pulmonary vascular arterial remodeling is an integral and well-understood component of pulmonary hypertension (PH). In contrast, morphological alterations of pulmonary veins in PH are scarcely described. Explanted lungs (n = 101) from transplant recipients with advanced chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary arterial hypertension (IPAH) were analyzed for venous vascular involvement according to a pre-specified, semi-quantitative grading scheme, which categorizes the intensity of venous remodeling in three groups of incremental severity: venous hypertensive (VH) g

APA, Harvard, Vancouver, ISO, and other styles

41

Hoffmann, Julia, Jochen Wilhelm, Andrea Olschewski, and Grazyna Kwapiszewska. "Microarray analysis in pulmonary hypertension." European Respiratory Journal 48, no. 1 (2016): 229–41. http://dx.doi.org/10.1183/13993003.02030-2015.

Full text

Abstract:

Microarrays are a powerful and effective tool that allows the detection of genome-wide gene expression differences between controls and disease conditions. They have been broadly applied to investigate the pathobiology of diverse forms of pulmonary hypertension, namely group 1, including patients with idiopathic pulmonary arterial hypertension, and group 3, including pulmonary hypertension associated with chronic lung diseases such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. To date, numerous human microarray studies have been conducted to analyse global (lung h

APA, Harvard, Vancouver, ISO, and other styles

42

Chauhan, Preeti, and Rajesh Chetiwal. "Renin angiotensin system and pulmonary hemodynamics in chronic obstructive pulmonary disease." International Journal of Advances in Medicine 5, no. 2 (2018): 404. http://dx.doi.org/10.18203/2349-3933.ijam20181078.

Full text

Abstract:

Background: Pulmonary hypertension in chronic obstructive pulmonary disease (COPD) due to chronic alveolar hypoxia is probably the main contributor to the pathogenesis of pulmonary hypertension in COPD. Angiotensin II is a potent vasoconstrictor in renin angiotensin aldosterone system (RAAS), it has been shown to promote growth response in vascular smooth muscle cell contributing towards pulmonary hypertension. So, the Echocardiographicaliy measured MPAP and its correlation with RAAS in patients of COPD was evaluated.Methods: A prospective observational study was done in 32 patients with COPD

APA, Harvard, Vancouver, ISO, and other styles

43

Glova, S. E., L. A. Khaisheva, I. V. Razumovsky, and S. V. Shlyk. "Microcirculatory changes in patients with chronic obstructive pulmonary disease and arterial hypertension." South Russian Journal of Therapeutic Practice 3, no. 1 (2022): 34–41. http://dx.doi.org/10.21886/2712-8156-2022-3-1-34-41.

Full text

Abstract:

Objective: to study the dynamics of microcirculation indices in patients with arterial hypertension, chronic obstructive pulmonary disease, and in their combination. Material and methods: the study included 226 people, of which 66 people were patients with chronic obstructive pulmonary disease, 54 patients with arterial hypertension, 74 people with a combination of chronic obstructive pulmonary disease and arterial hypertension, 32 relatively healthy volunteers. To assess the circulatory bed, we used a computerized ultrasonic Doppler instrument Minimax-Doppler-K, LLC JV «Minimax». Results: in

APA, Harvard, Vancouver, ISO, and other styles

44

王, 凯丽. "The Role of Platelet Activation in Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Hypertension." Advances in Clinical Medicine 12, no. 09 (2022): 8786–90. http://dx.doi.org/10.12677/acm.2022.1291268.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Wright, Joanne L., Hsin Tai, and Andrew Churg. "Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig." Journal of Applied Physiology 100, no. 2 (2006): 672–78. http://dx.doi.org/10.1152/japplphysiol.00274.2005.

Full text

Abstract:

The pathogenesis of pulmonary hypertension in patients with chronic obstructive pulmonary disease is not understood. We have previously shown increased levels of mediators that control vasoconstriction (endothelin-1), vascular cell proliferation (endothelin-1 and vascular endothelial growth factor), and vasodilation (endothelial nitric oxide synthase) in the intrapulmonary arteries of animals exposed to cigarette smoke. To determine whether these mediators could be implicated in the structural remodeling of the arterial vasculature and increased pulmonary arterial pressure caused by chronic ci

APA, Harvard, Vancouver, ISO, and other styles

46

Ismyilzada, Jeyhun Mokhubbat, and Rafig Idris Bayramov. "Pulmonary Arterial Hypertension in Patients with Chronic Obstructive Pulmonary Disease Combined with Lung Tuberculosis." Turkish Thoracic Journal 20, no. -1 (2019): 253. http://dx.doi.org/10.5152/turkthoracj.2019.253.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kim, Hyun-Sook, Jae-Hyeong Park, Seoung Ju Park, Jong Kwan Park, and Heung-Bum Lee. "Use of Tadalafil for Treating Pulmonary Arterial Hypertension Secondary to Chronic Obstructive Pulmonary Disease." Korean Journal of Internal Medicine 22, no. 1 (2007): 37. http://dx.doi.org/10.3904/kjim.2007.22.1.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Adir, Yochai, Marc Humbert, and Ari Chaouat. "Sleep-related breathing disorders and pulmonary hypertension." European Respiratory Journal 57, no. 1 (2020): 2002258. http://dx.doi.org/10.1183/13993003.02258-2020.

Full text

Abstract:

Sleep-related breathing disorders (SBDs) include obstructive apnoea, central apnoea and sleep-related hypoventilation. These nocturnal events have the potential to increase pulmonary arterial pressure (PAP) during sleep but also in the waking state. “Pure” obstructive sleep apnoea syndrome (OSAS) is responsible for a small increase in PAP whose clinical impact has not been demonstrated. By contrast, in obesity hypoventilation syndrome (OHS) or overlap syndrome (the association of chronic obstructive pulmonary disease (COPD) with obstructive sleep apnoea (OSA)), nocturnal respiratory events con

APA, Harvard, Vancouver, ISO, and other styles

49

Rakhimova, D., A. Alavi, and S. Nuritdinova. "VENTILATION AND PERFUSION CONDITION OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PULMONARY HYPERTENSION." POLISH JOURNAL OF SCIENCE, no. 74 (May 15, 2024): 26–30. https://doi.org/10.5281/zenodo.11195242.

Full text

Abstract:

To study interrelations psychological of factors regulations, and quality of life (QL) of the patients with remodeling right ventriculi of heart at the patients of chronic obstructive pulmonary disease. complicated by cor pulmonale on a background of treatment standarttherapy, ozonotherapy (OT) and phototherapy (FT). As a result of research have established, that OT and FT on a background of bazistherapy improve patogenesis the interconnected infringements that is psychological of factors regulations, parameters QL, diastolik function right ventriculi of heard and respiratory function (p <

APA, Harvard, Vancouver, ISO, and other styles

50

Suzuki, Takaaki, Kimihiko Hirose, Fumiko Tabei, et al. "An Autopsy Case of Pulmonary Veno-Occlusive Disease Complicated with Chronic Obstructive Pulmonary Disease and Severe Pulmonary Hypertension." International Heart Journal 62, no. 5 (2021): 1186–90. http://dx.doi.org/10.1536/ihj.21-133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!